Oh absolutely. I tried to keep it short and simple because explaining pharmacokinetic and pharmacodynamic factors is pretty tough, so they’re just included in the 100x safety factor that I talked about. The actual FDA recommendation is either a 6.2 multiplier to move from rat to human with a factor of 10 safety margin — i.e. divide by 62 — or just using 100 as a broad safety estimate.
In the actual California analysis they estimate pharmacodynamic/kinetic differences and come up with a ~3.2 conversion factor for acrylamide interspecies scaling based on the internal dose of glycidamide which is thought to be primarily responsible for mediating acrylamide carcinogenesis. Their analysis is incredibly thorough, it’s definitely worth a read: